Lung Cancer

Lung carcinoma cell growth is suppressed by rosiglitazone via two pathways

Published in Cancer Weekly, April 24th, 2006

According to research from the United States, lung carcinoma cell growth is suppressed by rosiglitazone through peroxisome proliferator-activated receptors gamma (PPAR-gamma)-dependent and PPAR gamma-independent signal pathways.

"PPAR gamma exert diverse effects on cancer cells. Recent studies showed that rosiglitazone, a synthetic ligand for PPAR gamma, inhibits cell growth. However, the exact mechanisms underlying this effect are still being explored, and the relevance of these findings to lung cancer remains unclear," wrote S.W. Han and colleagues, Emory University.

"Here," they continued, "we report that rosiglitazone reduced the phosphorylation...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-04-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry